Trial Profile
Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Cardamon
- 12 Dec 2023 Results testing hypothesis, in the context of consolidation or ASCT in patients enrolled in CARDAMON, whether patients with higher neoantigen load would gain most benefit from ASCT, due to immune reprogramming, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results assessing health-related quality of life and the impact of Autologous Stem Cell Transplant (ASCT) on the tolerability of maintenance, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition